Janux Therapeutics
Janux Therapeutics Inc is an American clinical-stage biopharmaceutical company developing novel T-cell engager immunotherapies for cancer treatment. The company utilizes its proprietary TRACTr and TRACER platforms to design tumor-activated therapeutics that selectively target cancer cells while sparing healthy tissue. Main revenue drivers currently stem from strategic pharmaceutical research collaborations, milestone payments, and capital markets financing as pipeline candidates advance. Janux Therapeutics targets oncology research centers, clinical trial investigators, and patients with solid tumors across North America and global markets. The company holds an innovative position in next-generation targeted T-cell engager biopharmaceutical development. Headquartered in San Diego, California, Janux Therapeutics Inc is listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Janux Therapeutics.
- Legal name
- Janux Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Janux Therapeutics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.07 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)